Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Study: Avastin Copycat ABP 215 Found Helpful In Lung Cancer

Study: Avastin Copycat ABP 215 Found Helpful In Lung Cancer

Posted on October 4, 2015
Post Views: 1,594

Study: Avastin Copycat ABP 215 Found Helpful In Lung CancerLung Cancer!!! People scared from it. Always say it’s a deadly disease. But now many treatments and drugs are developed, Out of these so many drugs one is Avastin Copycat ABP 215 – which found very helpful in lung cancer treatment and it increases the survival rate too.

In 2014, Roche’s Avastin is most sold lung cancer drug which reported shocking $6.5 billion in sales. The biosimilars (biosimilar are copied version of a biotechnology drug) of Avastin are beginning developing as drug called ABP 2015.

The stage 3 analysis of Amgen Inc. and Allergan Plc’s biosimilar applicant ABP 215 achieved a significant landmark. The analysis, which looked into its safety and effectiveness, produced appealing outcomes that made it at par with Roche having AG’s Avastin.

In March 2015, the U. S. Food and Drug Management (FDA) accepted the very first biosimilar lung cancer drug known as Zarxio. Produced by Novartis AG, Zarxio increases the performance of white blood tissues. Amgen Inc. was the original biosimilar owner of Avastin, but the organization fail to stop Zarxio’s release early in 2015 despite several legal cases.

Allergan’s chief professional of International Research and Development Bob Nicholson added that ABP 215’s successful medical outcomes is a crucial step in the growth of other biosimilars for innovative non-small cell lung cancer (NSCLC) sufferers.

The two drug organizations are in cooperation to generate four other biosimilars, the first of which is ABP 215. Upon receiving FDA acceptance, ABP 215 will be their very first biosimilar drug in the market. It will contend head-to-head with Novartis’ Zarxio and Roche’s Avastin. Individually, Amgen is working on eight more biosimilars.

The development of biosimilars for such a deadly disease drugs are definitely beneficial for medical groups, as these drugs easily and widely available in the market. Also by suggesting this drug more and more to patients will reduce the death rate among lung cancer patients.

It’s a great achievement for non-small cell lung cancer (NSCLC) sufferers.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,303)
  • Lung Cancer: Symptoms and Treatment (5,625)
  • What is Non-Small-Cell Lung Cancer? (5,531)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025
  • Understanding The Stage 0 Lung Cancer April 21, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha. Privacy Policy
%d